Holen Sie sich die Stockscreener-App
15.74
6.86%
1.01
Handel nachbörslich:
15.72
-0.02
-0.13%
Syndax Pharmaceuticals Inc Aktie (SNDX) Neueste Nachrichten
Aigen Investment Management LP Buys Shares of 24,158 Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Syndax Pharmaceuticals (SNDX) Is Up 15.8% After Revenue Surges in Q2 2025 Results Has Sentiment Shifted? - Yahoo Finance
Syndax Skyrockets 8.58%—Is This the Start of a Biotech Breakout? - AInvest
Does Syndax (SNDX) Have the Potential to Rally 158.36% as Wall Street Analysts Expect? - Zacks Investment Research
Syndax Pharmaceuticals: A Tale of Two Drug Launches - AInvest
Syndax Pharmaceuticals: A Tale Of Two Drug Launches (NASDAQ:SNDX) - Seeking Alpha
Stock Traders Purchase Large Volume of Call Options on Syndax Pharmaceuticals (NASDAQ:SNDX) - MarketBeat
FDA Priority Review and Revenue Growth Drive Short-Term Upswing for Syndax Pharmaceuticals - Insider Monkey
Syndax Pharmaceuticals' Path to Blockbuster Status: Leveraging FDA Priority Review and Revenue Growth in Oncology - AInvest
S&E In Brief: Launch Updates And Political Headwinds - insights.citeline.com
What makes Syndax Pharmaceuticals Inc. stock price move sharplyLow Cost High Gain Picks - mustnews.co.kr
Syndax Pharmaceuticals (NASDAQ:SNDX) Upgraded by B. Riley to Strong-Buy Rating - MarketBeat
Syndax jumps after Q2 beat; Citi issues upside catalyst watch - MSN
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Analysts Just Made A Massive Upgrade To Their Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Forecasts - 富途牛牛
Analysts Boost Syndax Pharmaceuticals' Forecasts, Revenue and EPS Estimates Increase - AInvest
Analysts Just Made A Dazzling Upgrade To Their Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Forecasts - Yahoo Finance
11 Best Short-Term Stocks to Invest in - Insider Monkey
Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Gap Up on Better-Than-Expected Earnings - MarketBeat
Syndax Pharmaceuticals Publishes Positive Revumenib Data from BEAT AML Trial - MSN
Q3 Earnings Forecast for SNDX Issued By B. Riley - MarketBeat
Citigroup Increases Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target to $51.00 - MarketBeat
BTIG Research Forecasts Strong Price Appreciation for Syndax Pharmaceuticals (NASDAQ:SNDX) Stock - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Issues Quarterly Earnings Results, Beats Estimates By $0.18 EPS - MarketBeat
Citi Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Announces Target Price $51 - 富途牛牛
Citi Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $51 - 富途牛牛
XTX Topco Ltd Invests $783,000 in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat
Syndax targets expanded $10B market opportunity with Revuforj and Niktimvo amid accelerating adoption and guidance for stable expenses - MSN
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Syndax Pharmaceuticals Announces Inducement Stock Grants Under NASDAQ Listing Rule 5635(c)(4) - AInvest
Citi Raises Syndax Target to $51, Adds Positive Catalyst Watch - AInvest
Citi ups Syndax target, opens ‘upside catalyst watch’ - Yahoo Finance
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q2 2025 Earnings Call Transcript - Insider Monkey
Three Stocks to Buy Now: Harmony Biosciences, Syndax Pharmaceuticals, and Viper Energy - AInvest
Optimistic Investors Push Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Up 40% But Growth Is Lacking - simplywall.st
Syndax Pharmaceuticals Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Syndax Pharmaceuticals Faces Ongoing and Emerging Business Risks: A Closer Look at SEC Filings - TipRanks
Decoding Syndax Pharmaceuticals Inc (SNDX): A Strategic SWOT Ins - GuruFocus
Citigroup Raises SNDX Price Target Amid "Buy" Rating - AInvest
Syndax Pharmaceuticals’ Earnings Call Highlights Robust Growth - TipRanks
Syndax Pharmaceuticals (SNDX) Reports Q2 Loss, Beats Revenue Estimates - MSN
Syndax Pharmaceuticals Wins Over Wall Street With Strong Drug Gains - Finimize
Syndax Reports Losses, But Wall Street Still Sees Big Upside - Finimize
Evaluating the High-Growth Potential of Biopharma Innovators in 2025: A Deep Dive into Day One, Beam Therapeutics, and Syndax Pharmaceuticals - AInvest
Syndax Pharmaceuticals Shares Rise After Q2 Results Beat - MarketScreener
Citigroup Raises Syndax PT to $51 from $46, Maintains Buy Rating - AInvest
Syndax Pharmaceuticals (SNDX) Surges on Strong Q2 2025 Results - GuruFocus
BTIG Raises Price Target for SNDX, Maintains Buy Rating | SNDX S - GuruFocus
Syndax Pharmaceuticals Q2 Earnings Exceed Expectations, Citi Issues Upside Catalyst Watch - AInvest
Syndax stock up as Citi issues catalyst watch (SNDX:NASDAQ) - Seeking Alpha
Syndax Stock (SNDX) Moves Higher: Analysts Raise PTs on Strong Revenue, Approaching Catalyst - AskTraders.com
Syndax Pharmaceuticals: The Story Brightens (NASDAQ:SNDX) - Seeking Alpha
Syndax Pharmaceuticals shares surge 17.44% intraday after Q2 earnings beat expectations, driven by strong revenue from Revuforj and Niktimvo. - AInvest
0.41%
0.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):